In May, the U.S. Preventative Services Task Force issued a document that recommended against routine PSA screening for prostate cancer (PCa).
It based that recommendation on its conclusion, based on a review of scientific evidence, that there is “moderate or high certainty that the service has no net benefit or that the harms outweigh the benefit.”
Although some men may benefit from having PCa detected early through PSA screening, the task force contends there is no conclusive evidence that routine PSA screening save lives, and noted that false-positive PSA test results can cause psychological harm and lead to prostate biopsies, which can cause discomfort.
Continue Reading
Renal & Urology News would like to know how the task force’s recommendation has affected urologists’ practices, so please answer the following poll question:
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.